Cue Health, a health-care-tech company has been awarded a $13 million contract to develop, and obtain FDA clearance of, a portable molecular diagnostic test capable of detecting SARS-CoV-2 — the virus that causes COVID-19 — in less than 25 minutes using a nasal swab, the company announced.
According to Cue, the test is part of the Cue Health Monitoring System, a portable device for performing a molecular test and connecting the patient to a mobile platform that features components such as tele-medicine consultations.
Cue said the funding was awarded by BARDA, Biomedical Advanced Research and Development Authority, part of the HHS Office of the Assistant Secretary for Preparedness and Response.
